Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
Tuesday, October 12, 2010 - 18:01
in Health & Medicine
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.